Trial Profile
A Pilot Trial Examining Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic Stem Cell Transplant Recipients Using Myeloablative Busulfan and Fludarabine
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Oct 2023
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Fludarabine (Primary) ; Antithymocyte globulin; Methotrexate
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Myeloid leukaemia; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Acronyms FluBuATG
- 17 Oct 2023 Status changed from active, no longer recruiting to completed.
- 19 May 2022 Planned End Date changed from 1 Dec 2021 to 1 Jun 2022.
- 29 Jan 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.